BLA 020162 · Ferring
Acthrel
Corticorelin Ovine Triflutate · Injection
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 1, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
May 23, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 23, 1996 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- ACTHREL · CORTICORELIN OVINE TRIFLUTATE EQ 0.1MG BASE/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Corticorelin Ovine Triflutate" as an intervention, any sponsor and status, largest first.
University of MichiganAcademic, hospital or other
NCT01673087 · 256 participants · Start Oct 2012 · Primary completion Aug 15, 2017
Drug: Metyrapone; Dexamethasone and 2 more · For: Stress
Sites: Ann Arbor, Michigan
- Hormonal Mechanisms of Sleep Restriction - Axis StudyActive, not recruiting
Peter y. LiuAcademic, hospital or other
NCT03142893 · 80 participants (planned) · Start May 8, 2017 · Primary completion Oct 30, 2020
Drug: Ketoconazole Pill; Ganirelix and 10 more · For: Sleep Restriction
Sites: Torrance, California
National Institute of Neurological Disorders and Stroke (NINDS)NIH
NCT01459237 · 30 participants · Start Oct 11, 2011 · Primary completion Jan 30, 2018
Drug: Acthrel · For: Pituitary Neoplasm
Sites: Bethesda, Maryland
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal WomenActive, not recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterAcademic, hospital or other
NCT04037605 · 5 participants · Start Feb 9, 2020 · Primary completion Jul 24, 2022
Drug: Ketoconazole Pill (also known as nizoral); Ganirelix and 10 more · For: Sleep Restriction
Sites: Torrance, California
Children's Mercy Hospital Kansas CityAcademic, hospital or other
NCT01373372 · 0 participants · Start Dec 2016 · Primary completion Dec 2016
Drug: Acthrel · For: Functional Dyspepsia
Sites: Kansas City, Missouri
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Ferring
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.